Cannabidiol alleviates carbon tetrachloride-induced liver fibrosis in mice by regulating NF-κB and PPAR-α pathways
Experimental Biology and Medicine · 22.04.2024 · 249
DOI: 10.3389/ebm.2024.10141 ↗Kurz gefasst
Fachartikel in der Zeitschrift Experimental Biology and Medicine, online erschienen am 22.04.2024. Verfasst von Run Ma und 7 weiteren Autor:innen. Beteiligte Einrichtung: Center for Clinical Laboratories, The Affiliated Hospital of Guizhou Medical University, Guiyang, Guizhou, China. Hauptthemen laut MEDLINE: Cannabidiol, NF-kappa B, PPAR alpha, Liver Cirrhosis. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 62 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Liver fibrosis has become a serious public health problem that can develop into liver cirrhosis and hepatocellular carcinoma and even lead to death. Cannabidiol (CBD), which is an abundant nonpsychoactive component in the cannabis plant, exerts cytoprotective effects in many diseases and under pathological conditions. In our previous studies, CBD significantly attenuated liver injury induced by chronic and binge alcohol in a mouse model and oxidative bursts in human neutrophils. However, the effects of CBD on liver fibrosis and the underlying mechanisms still need to be further explored. A mouse liver fibrosis model was induced by carbon tetrachloride (CCl 4 ) for 10 weeks and used to explore the protective properties of CBD and related molecular mechanisms. After the injection protocol, serum samples and livers were used for molecular biology, biochemical and pathological analyses. The results showed that CBD could effectively improve liver function and reduce liver damage and liver fibrosis progression in mice; the expression levels of transaminase and fibrotic markers were reduced, and histopathological characteristics were improved. Moreover, CBD inhibited the levels of inflammatory cytokines and reduced the protein expression levels of p-NF-κB, NF-κB, p-IκBα, p-p38 MAPK, and COX-2 but increased the expression level of PPAR-α. We found that CBD-mediated protection involves inhibiting NF-κB and activating PPAR-α. In conclusion, these results suggest that the hepatoprotective effects of CBD may be due to suppressing the inflammatory response in CCl 4 -induced mice and that the NF-κB and PPAR-α signaling pathways might be involved in this process.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Center for Clinical Laboratories, The Affiliated Hospital of Guizhou Medical University, Guiyang, Guizhou, China.
- School of Clinical Laboratory Science, Guizhou Medical University, Guiyang, Guizhou, China.
- Sichuan Provincial Center for Disease Control and Prevention, Chengdu, Sichuan, China.
- Clinical Laboratory, The Fourth People's Hospital of Ya'an City, Ya'an, Sichuan, China.
- Pathology, The Affiliated Hospital of Guizhou Medical University, Guiyang, Guizhou, China.
Zitieren
APA
Ma, R., Xie, N., Shu, Y., Wu, Y., He, P., Xiang, Y., Zhou, Y., & Wang, Y. (2024). Cannabidiol alleviates carbon tetrachloride-induced liver fibrosis in mice by regulating NF-κB and PPAR-α pathways. Experimental Biology and Medicine, 249. https://doi.org/10.3389/ebm.2024.10141
Vancouver
Ma R, Xie N, Shu Y, Wu Y, He P, Xiang Y, et al. Cannabidiol alleviates carbon tetrachloride-induced liver fibrosis in mice by regulating NF-κB and PPAR-α pathways. Experimental Biology and Medicine. 2024;249. doi:10.3389/ebm.2024.10141
BibTeX
@article{Ma2024,
author = {Ma, Run and Xie, Na and Shu, Yuanhui and Wu, Yafeng and He, Ping and Xiang, Yining and Zhou, Yan and Wang, Yuping},
title = {Cannabidiol alleviates carbon tetrachloride-induced liver fibrosis in mice by regulating NF-κB and PPAR-α pathways},
journal = {Experimental Biology and Medicine},
year = {2024},
volume = {249},
doi = {10.3389/ebm.2024.10141}
}
EUVIMED